Afinitor (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease. Based on results from this study and other early-stage research,
China Biologic Products has entered into a securities purchase agreement with certain accredited investors led by Essence International Investment. As per the deal, the company will issue 3.8%
Sinovac has announced that it has initiated the production of a vaccine against influenza A (H1N1) virus. The virus seed was received from US CDC, and was delivered
Cyclacel scientists have reported preclinical data supporting potential combinations of sapacitabine (a novel nucleoside analog) with novel targeted agents and other nucleoside analogs, for the treatment of cancer.
Rx for Africa has announced the signing of letter of intent for a strategic alliance with Rusan Pharma of Mumbai, India. The alliance commences immediately, with Rusan providing
Lundbeck and Takeda jointly announced headline results from the first three clinical trials in the phase III development program with Lu AA21004, in major depressive disorder (MDD). Previously
Custom health communications company, StayWell Custom Communications (SCC), a division of MediMedia US, has announced an exclusive strategic alliance with Siteimprove. The alliance is intended to provide value
New Phase II data showed that the investigational type 2 diabetes treatment Syncria (albiglutide) has reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly
Novo Nordisk has reported that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight, after two years of treatment.
Amgen has reported the results of a new study comparing Nplate (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.